NCT03570294

Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

Completed NA Last updated 14 June 2019

What this trial tests

NA trial testing Atosiban in Premature Birth in 64 participants. Completed in 30 December 2018.

Timeline

1 February 2014

Primary endpoint
10 June 2018

30 December 2018

Quick facts

Lead sponsor	Polish Mother Memorial Hospital Research Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	1 February 2014
Primary completion	10 June 2018
Estimated completion	30 December 2018
Sites	1 location across Poland

Drugs / interventions tested

• Atosiban (ATOSIBAN) — full drug profile →

Conditions studied

• Premature Birth — all drugs for Premature Birth →

Sponsor

Polish Mother Memorial Hospital Research Institute

Who can join

Adults 18 to 45, female only, with Premature Birth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oxidative stress is recognized as a important factor in the pathogenesis premature birth. Preterm birth is defined as delivery before 37 completed weeks of gestation and it is the leading cause of neonatal morbidity and mortality. The investigators conducted this analysis to investigate the safety of administration of Atosiban - a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm labor and its impact on the level of oxidative stress after 48 hours of tocolytic treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth.
   Grzesiak M, Gaj Z, Kocyłowski R, Suliburska J, et al · · 2018 · cited 12× · PMID 30622667 · DOI 10.1155/2018/3919106